hepatitis virus
Recently Published Documents


TOTAL DOCUMENTS

2420
(FIVE YEARS 270)

H-INDEX

93
(FIVE YEARS 9)

Author(s):  
Muhammad Riaz ◽  
◽  
Majid Khan ◽  
Rizwan Ahmad ◽  
Lina Hussain AlLehaibi ◽  
...  

Currently, the whole world is facing a life-threatening novel coronavirus 2019 (COVID-19) pandemic. Natural products are well-known for their potential role against viral disease, and some anti-viral agents have been developed to combat these diseases. Herein, the authors investigated the possible effects of this Holy plant Nigella sativaL. (NS), against coronavirus, using evidence-based and mechanistic approaches to conclude the immune-boosting and alleviation of respiratory systemeffects of NS. The pharmacological studies established a prominent role in treating various respiratory, immune systems, cardiovascular, skin, and gastrointestinal disorders. Literature supported the significant anti-viral role and showed an inhibitory role for NS against MHV-A59 CoV (mouse-hepatitis virus–A59) infected Hela, i.e., HeLaCEACAM1a (HeLa-epithelial carcinoembryonic antigen-related cell adhesion molecule 1a) cell. NS is a safe herbal product or dietary supplement and could be an effective and affordable community adjuvant treatment for coronavirus in the current scenario.


Author(s):  
Luis A. Caldera-Crespo ◽  
Michael J. Paidas ◽  
Sabita Roy ◽  
Carl I. Schulman ◽  
Norma Sue Kenyon ◽  
...  

COVID-19 is the most consequential pandemic of the 21st century. Since the earliest stage of the 2019-2020 epidemic, animal models have been useful in understanding the etiopathogenesis of SARS-CoV-2 infection and rapid development of vaccines/drugs to prevent, treat or eradicate SARS-CoV-2 infection. Early SARS-CoV-1 research using immortalized in-vitro cell lines have aided in understanding different cells and receptors needed for SARS-CoV-2 infection and, due to their ability to be easily manipulated, continue to broaden our understanding of COVID-19 disease in in-vivo models. The scientific community determined animal models as the most useful models which could demonstrate viral infection, replication, transmission, and spectrum of illness as seen in human populations. Until now, there have not been well-described animal models of SARS-CoV-2 infection although transgenic mouse models (i.e. mice with humanized ACE2 receptors with humanized receptors) have been proposed. Additionally, there are only limited facilities (Biosafety level 3 laboratories) available to contribute research to aid in eventually exterminating SARS-CoV-2 infection around the world. This review summarizes the most successful animal models of SARS-CoV-2 infection including studies in Non-Human Primates (NHPs) which were found to be susceptible to infection and transmitted the virus similarly to humans (e.g., Rhesus macaques, Cynomolgus, and African Green Monkeys), and animal models that do not require Biosafety level 3 laboratories (e.g., Mouse Hepatitis Virus models of COVID-19, Ferret model, Syrian Hamster model). Balancing safety, mimicking human COVID-19 and robustness of the animal model, the Murine Hepatitis Virus-1 Murine model currently represents the most optimal model for SARS-CoV-2/COVID19 research. Exploring future animal models will aid researchers/scientists in discovering the mechanisms of SARS-CoV-2 infection and in identifying therapies to prevent or treat COVID-19.


2022 ◽  
Vol 5 (1) ◽  
pp. 5
Author(s):  
Tautvydas Shuipys ◽  
Naim Montazeri

Murine hepatitis virus (MHV) is a non-human pathogen betacoronavirus that is evolutionarily and structurally related to the human pathogenic viruses SARS-CoV, MERS-CoV, and SARS-CoV-2. However, unlike the human SARS and MERS viruses, MHV requires a biosafety level 2 laboratory for propagating and safe handling, making it a potentially suitable surrogate virus. Despite this utility, few papers discussed the propagation and quantification of MHV using cell lines readily available in biorepositories making their implementations not easily reproducible. This article provides protocols for propagating and quantifying MHV-A59 using the recommended NCTC clone 1469 and clone 929 cell lines from American Type Culture Collection (ATCC). More specifically, the methods detail reviving cells, routine cell passaging, preparing freeze stocks, infection of NCTC clone 1469 with MHV and subsequent harvesting, and plaque assay quantification of MHV using NCTC clone 929 cells. Using these protocols, a BSL-2 laboratory equipped for cell culture work would generate at least 6.0 log plaque-forming units (PFU) per mL of MHV lysate and provide an optimized overlay assay using either methylcellulose or agarose as overlays for the titration of infectious virus particles. The protocols described here are intended to be utilized for persistence and inactivation studies of coronaviruses.


Kanzo ◽  
2022 ◽  
Vol 63 (1) ◽  
pp. 9-15
Author(s):  
Yukiteru Yanabe ◽  
Fusao Ikeda ◽  
Shin-ichi Fujioka ◽  
Hiromi Endo ◽  
Masayo Hirata ◽  
...  

Diagnostics ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 14
Author(s):  
Barbara Rossetti ◽  
Valentina Borgo ◽  
Arianna Emiliozzi ◽  
Marta Colaneri ◽  
Giacomo Zanelli ◽  
...  

Severe liver fibrosis (LF) is associated with poor long-term liver-related outcomes in people living with HIV (PLWH). The study aimed to explore the prevalence and predictors of LF and the concordance between different non-invasive methods for the estimation of LF in HIV-infected individuals without hepatitis virus infection. We enrolled PLWH with HIV-1-RNA <50 copies/mL for >12 months, excluding individuals with viral hepatitis. LF was assessed by transient elastography (TE) (significant >6.65 kPa), fibrosis-4 (FIB-4) (significant >2.67), and AST-to-platelet ratio index (APRI) (significant >1.5). We included 234 individuals (67% males, median age 49 years, median time from HIV diagnosis 11 years, 38% treated with integrase strand transfer inhibitors). In terms of the TE, 13% had ≥F2 stage; FIB-4 score was >1.5 in 7%; and APRI > 0.5 in 4%. Higher body mass index, diabetes mellitus, detectable baseline HIV-1 RNA and longer atazanavir exposure were associated with higher liver stiffness as per TE. Predictors of higher APRI score were CDC C stage and longer exposure to tenofovir alafenamide, while HBcAb positivity and longer exposure to tenofovir alafenamide were associated to higher FIB-4 scores. Qualitative agreement was poor between FIB-4/TE and between APRI/TE by non-parametric Spearman correlation and kappa statistic. In our study, in the group of PLWH without viral hepatitis, different non-invasive methods were discordant in predicting liver fibrosis.


2021 ◽  
Author(s):  
Ana C. Puhl ◽  
Giovanni F. Gomes ◽  
Samara Damasceno ◽  
Ethan J. Fritch ◽  
James A. Levi ◽  
...  

The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib) or in advanced clinical trials. We have tested 45 FDA-approved kinase inhibitors in vitro against murine hepatitis virus (MHV) as a model of SARS-CoV-2 replication and identified 12 showing inhibition in the delayed brain tumor (DBT) cell line. Vandetanib, which targets the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase showed the most promising results on inhibition versus toxic effect on SARS-CoV-2-infected Caco-2 and A549-hACE2 cells (IC50 0.79 uM) while also showing a reduction of > 3 log TCID50/mL for HCoV-229E. The in vivo efficacy of vandetanib was assessed in a mouse model of SARS-CoV-2 infection and statistically significantly reduced the levels of IL-6, IL-10, TNF-a;, and mitigated inflammatory cell infiltrates in the lungs of infected animals but did not reduce viral load. Vandetanib rescued the decreased IFN-1b; caused by SARS-CoV-2 infection in mice to levels similar to that in uninfected animals. Our results indicate that the FDA-approved vandetanib is a potential therapeutic candidate for COVID-19 positioned for follow up in clinical trials either alone or in combination with other drugs to address the cytokine storm associated with this viral infection.


2021 ◽  
Author(s):  
Andreas Wieser ◽  
Jessica Beyerl ◽  
Albrecht von Brunn ◽  
Vincent Rieker ◽  
Marcus Rieker ◽  
...  

Background: The SARS-CoV-2 pandemic demonstrated the vulnerability of our societies to aerosol transmitted pathogens. With no less than 260mio known cases and >5mio deaths, SARS-CoV-2 is a global catastrophe leading to human and economic losses unprecedented in recent history. Thus, effective methods to limit the spread of aerosol transmitted pathogens are needed. Universal masking and curfew laws are effective but no permanent solution. Methods: A mass producible LED light source emitting homogeneous parallel UV-C light was used as a light-barrier to block the spread of infectious aerosols. In an aerosol test channel, Gram-negative and Gram-positive bacteria as well as coronavirus were nebulized and inactivation rates were determined. Findings: With air speeds of 0.1ms-1 an exposure time of 1s in the UV-C light is obtained. Reduction in CFU for E. coli was >3log10 and for S. aureus ~2.8log10. Plug-forming-units of the murine coronavirus (Mouse Hepatitis Virus, MHV) were reduced by about 3log10. Interpretation: The concept of a UV-C light barrier to ward off infectious aerosols if feasible and possible with a light element as described here. Coupled with sensor based activation/deactivation, such a technology could greatly reduce the transmission rates of aerosol transmitted pathogens while not disturbing natural human behaviour. This is an interesting technology allowing a new normal in societies after/with SARS-CoV-2.


Sign in / Sign up

Export Citation Format

Share Document